Clostridium novyi-NT Photo: Journal of Bacteriology
Bacteria may offer a new way to treat cancer, according with a study presented last Saturday at the annual Symposium on Clinical Interventional Oncology in Hollywood. Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.
Environments reduced in oxygen, as those occurring in tumors, are favorable for Clostridium subspecies to germinate. Previous studies showed that Clostridium novyi-NT (C. novyi-NT) induced a microscopic & tumor-confined lysis after intratumoral injection in rat orthotopic brain tumor models & spontaneous solid tumors in dogs.
Now this group of researchers is using this method in a first-in-man phase 1 study. Researchers choose six voluntary patients with therapy-refractory solid tumors palpable or identifiable under imaging guidance. Then they injected a weakened strain of Clostridium novyi-NT bacteria spores into their tumors.
According with the researchers, the bacteria grew in the tumors and killed cancer cells. Five of the six patients are still alive, while one died from unrelated causes several months after receiving the bacteria injection.
C. novyi-NT, which lives in soil, is a close relative of the bacteria that causes botulism. Before injecting C. novyi-NT into the patients, the researchers weakened it by removing its dangerous toxin.
“When tumors reach a certain size, parts of them do not receive oxygen, which makes them resistant to conventional therapies such as radiation and chemotherapy,” study author Dr. Ravi Murthy, a professor of interventional radiology at M.D. Anderson Cancer Center in Houston, said in a symposium news release. “C. novyi-NT thrives under these conditions, hones in on the low-oxygen areas and destroys tumors from the inside while sparing normal tissue,” Murthy explained.
Another interesting characteristic of C. novyi-NT is that it also triggers an immune response to cancer.
“Essentially, C. novyi-NT causes a potent cancer-killing infection in the tumor,” study principal investigator Dr. Filip Janku, an associate professor in the department of investigation therapeutics at M.D. Anderson Cancer Center, said in the news release.
The new findings resulted from a first clinical trial, which means that are very preliminary and much additional research into the potential therapy is needed.
Soruce: Health Library
